PCR Techniques of Dried Sputum Using a Spotcard

Sponsor
University Medical Center Groningen (Other)
Overall Status
Recruiting
CT.gov ID
NCT04055584
Collaborator
(none)
8
1
30
0.3

Study Details

Study Description

Brief Summary

Molecular testing for mutations in M. tuberculosis genes associated to resistance of anti tuberculosis (TB) drugs is already part of standard laboratory TB diagnostic.

This implicates earlier knowledge of possible resistance and thus prevents unnecessary treatment and the chance of treatment failure or treatment related toxicity.

The molecular laboratory diagnostics is widely spread in high income, low TB endemic countries. However, the low income countries lack widespread facilities to test for susceptibility, either genotypic or phenotypic. Performing molecular diagnostics on sputum collected with a spot card could improve accessibility to molecular testing.

This study examines if sputum collected and put on spot cards could be used for multiple molecular tests for the detection, identification and susceptibility prediction of TB. This means that DNA extraction of the sputum from the spot card should be feasible.

The study is a pilot study with adult patients of the tuberculosis department of University Medical Centre Groningen (UMCG) Beatrixoord, Haren as subjects. The sputum produced will be collected, dried on spot cards, and DNA extraction from the card will be tested. If molecular detection is positive for the tuberculosis bacteria additional tests will be performed. Based on the present/absent of mutations in the genes associated to resistance susceptibility can be preditec, different molecular techniques will be performed to identify possible mutations. Furthermore, sputum will be collected as patients produce so. Sputum samples with low bacterial load can be tested as well and can test the sensitivity of the procedure.

Lastly, techniques like RNA detection will be tested to identify the bacterial load. This can be done if more than one sample of patients were collected.

Subjects will be selected on age, participation in standard TDM and drug use. Demographic parameters will be analysed. Sputum samples will be taken twice a week (on Tuesday and Friday).

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Sputum

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
8 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
PCR Techniques of Dried Sputum Using a Spotcard
Actual Study Start Date :
Jul 2, 2019
Anticipated Primary Completion Date :
Nov 30, 2021
Anticipated Study Completion Date :
Dec 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Sputum spot

Diagnostic Test: Sputum
DNA extraction and perform a diversity of molecular diagnostic tests

Outcome Measures

Primary Outcome Measures

  1. Is it possible to perform a diversity of molecular diagnostic TB tests and in addition new next generation sequencing approaches, with the DNA from the dried sputum spots? [6 months]

    Is it possible to perform a diversity of molecular diagnostic TB tests and in addition new next generation sequencing approaches, with the DNA from the dried sputum spots?

Secondary Outcome Measures

  1. Can we use DNA detection of the sputum from the dried card to certify that in the final utilisation format both the sputum and blood (not collected or tested in this study) are from the same patient? [6 months]

    Can we use DNA detection of the sputum from the dried card to certify that in the final utilisation format both the sputum and blood (not collected or tested in this study) are from the same patient?

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients is 18 years or older

  • Pulmonary TB confirmed by culture or molecular test

  • Producing sputum

  • Signed informed consent

Exclusion Criteria:
  • Extrapulmonary TB

  • Pulmonary TB without production of sputum

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Medical Center Groningen Groningen Netherlands

Sponsors and Collaborators

  • University Medical Center Groningen

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Onno Akkerman, Principal Investigator, University Medical Center Groningen
ClinicalTrials.gov Identifier:
NCT04055584
Other Study ID Numbers:
  • PCR techniques of dried sputum
First Posted:
Aug 14, 2019
Last Update Posted:
May 3, 2021
Last Verified:
Apr 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 3, 2021